Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health
Peter Falkai,Nikolaos Koutsouleris,Katja Bertsch,Mirko Bialas,Elisabeth Binder,Markus Bühner,Alena Buyx,Na Cai,Silvia Cappello,Thomas Ehring,Jochen Gensichen,Johannes Hamann,Alkomiet Hasan,Peter Henningsen,Stefan Leucht,Karl Heinz Möhrmann,Elisabeth Nagelstutz,Frank Padberg,Annette Peters,Lea Pfäffel,Daniela Reich-Erkelenz,Valentin Riedl,Daniel Rueckert,Andrea Schmitt,Gerd Schulte-Körne,Elfriede Scheuring,Thomas G Schulze,Rudolf Starzengruber,Susanne Stier,Fabian J Theis,Juliane Winkelmann,Wolfgang Wurst,Josef Priller
DOI: https://doi.org/10.3389/fpsyt.2022.815718
2022-03-04
Abstract:The Federal Ministry of Education and Research (BMBF) issued a call for a new nationwide research network on mental disorders, the German Center of Mental Health (DZPG). The Munich/Augsburg consortium was selected to participate as one of six partner sites with its concept "Precision in Mental Health (PriMe): Understanding, predicting, and preventing chronicity." PriMe bundles interdisciplinary research from the Ludwig-Maximilians-University (LMU), Technical University of Munich (TUM), University of Augsburg (UniA), Helmholtz Center Munich (HMGU), and Max Planck Institute of Psychiatry (MPIP) and has a focus on schizophrenia (SZ), bipolar disorder (BPD), and major depressive disorder (MDD). PriMe takes a longitudinal perspective on these three disorders from the at-risk stage to the first-episode, relapsing, and chronic stages. These disorders pose a major health burden because in up to 50% of patients they cause untreatable residual symptoms, which lead to early social and vocational disability, comorbidities, and excess mortality. PriMe aims at reducing mortality on different levels, e.g., reducing death by psychiatric and somatic comorbidities, and will approach this goal by addressing interdisciplinary and cross-sector approaches across the lifespan. PriMe aims to add a precision medicine framework to the DZPG that will propel deeper understanding, more accurate prediction, and personalized prevention to prevent disease chronicity and mortality across mental illnesses. This framework is structured along the translational chain and will be used by PriMe to innovate the preventive and therapeutic management of SZ, BPD, and MDD from rural to urban areas and from patients in early disease stages to patients with long-term disease courses. Research will build on platforms that include one on model systems, one on the identification and validation of predictive markers, one on the development of novel multimodal treatments, one on the regulation and strengthening of the uptake and dissemination of personalized treatments, and finally one on testing of the clinical effectiveness, utility, and scalability of such personalized treatments. In accordance with the translational chain, PriMe's expertise includes the ability to integrate understanding of bio-behavioral processes based on innovative models, to translate this knowledge into clinical practice and to promote user participation in mental health research and care.